Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET

Company Participants

Kimberly Lee - Chief Corporate Affairs Officer

RA Session - President, Founder and Chief Executive Officer

Suyash Prasad - Chief Medical Officer and Head of Research and Development

Kamran Alam - Chief Financial Officer

Fred Porter - Chief Technical Officer

Conference Call Participants

Gil Blum - Needham & Company, LLC

Geulah Livshits - Chardan

Mehdi Goudarzi - Truist Securities

Michael Ulz - Morgan Stanley

David Hoang - SMBC Nikko

Benjamin Paluch - Robert W. Baird

Yanan Zhu - Wells Fargo

Tiffany Marchell - William Blair

Whitney Ijem - Canaccord Genuity

Operator

Thank you for standing by. Welcome to Taysha Gene Therapies Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, November 8, 2022.

I will now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.

Kimberly Lee

Good morning, and welcome to Taysha's third quarter 2022 financial results and corporate update conference call. Joining me on today's call are RA Session, II Taysha's President, Founder and CEO; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; and Kamran Alam, Chief Financial Officer. After our formal remarks, we will conduct a question-and-answer session and instructions will follow at that time.

Earlier today, Taysha issued a press release announcing financial results for the second quarter ending September 30, 2022. A copy of this press release is available on the company's website and through our SEC filings.

Please note that, on today's call, we will be making forward-looking statements, including statements relating to the safety and efficacy and the therapeutic and commercial potential of our investigational product candidates, as well as the strategic investment by Astellas, including the potential for Astellas to exercise any other options we granted to them. This call may also contain forward-looking statements relating to Taysha's growth and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not of historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements.

These risks include uncertainties related to the timing and results of clinical trials and preclinical studies of our product candidates or dependence upon strategic alliances and other third-party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties and the requirements of substantial funding to conduct our research and development activities. For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the Securities and Exchange Commission.